Navigation Links
Soligenix Reports Second Quarter 2010 Financial Results and Reviews Accomplishments
Date:8/13/2010

PRINCETON, N.J., Aug. 13 /PRNewswire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin Board: www.soligenix.com.

This press release contains forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes," "intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec®, SGX201, RiVax™, and LPMTM, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Soligenix Announces Private Equity Financing of $5.16 Million With Its Partner Sigma-Tau and Other Institutional Investors
2. Soligenix Announces Grant of US Patent for the Treatment of Irritable Bowel Syndrome with Oral Beclomethasone Dipropionate
3. Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments
4. Soligenix Announces Completion of Patient Enrollment in Phase 2 Acute GVHD Prevention Clinical Trial
5. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
6. Soligenix to Present at 12th Annual BIO CEO & Investor Conference
7. Soligenix Reports Third Quarter 2009 Financial Results
8. Soligenix to Present at 8th Annual BIO Investor Forum
9. Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
10. DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX
11. Oncothyreon reports second quarter 2010 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  ECC West Africa, ... Colorado with University College Hospital (UCH) Ibadan ... development project to finance, design, construct, and operate and ... Nigeria . Under the first of the ... scoping documents and funding applications. UCH Ibadan intends to ...
(Date:7/24/2014)... materialise. Yet, scientists are making progress in devising ... such approach relies on quantum dotsa kind of ... field. A new study demonstrates that changing the ... with electrical impulses can help better control them. ... used as quantum information units, which would produce ...
(Date:7/24/2014)... , July 24, 2014 Research ... "Global Cell Culture Market 2014-2018" report to ... Cell culture is the in vitro growth ... as research, cell studies, and biopharmaceutical production. Cell culture ... production. Cell culture instruments and cell culture consumables are ...
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 /PRNewswire/ ... million, seven-year contract with the National Institute of Allergy ... of Health, to conduct preclinical development of potential therapies ... development of drugs to treat HIV and AIDS and ... as well as microbicides for preventing sexual transmission of ...
Breaking Biology Technology:ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3
... 28, 2011 TriLink BioTechnologies, Inc. (TriLink) and Lucigen ... signed a licensing agreement for the use of TriLink,s ... MasterMix. TriLink,s CleanAmp™ dNTPs are an innovative ... standard dNTPs in a PCR assay with CleanAmp™ dNTPs, ...
... SILVER SPRING, Md., July 28, 2011 United Therapeutics Corporation ... for the quarter ended June 30, 2011. "I,m ... quarter, as well as the very good operating results we ... Executive Officer. "We remain on track to reach our 2011 ...
... Mass., July 27, 2011 SomaLogic, Inc. ... today that they have entered into an ... specific SOMAmers as critical and unique reagents ... acid amplification and polymerase chain reaction (PCR) ...
Cached Biology Technology:TriLink BioTechnologies, Inc. Announces License Agreement with Lucigen Corporation 2United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 7Agreement Between SomaLogic and New England Biolabs Enables the Use of SOMAmer Technology for the Optimization of Multiple PCR Products 2
(Date:7/24/2014)... specialist at The University of Texas Health Science Center ... grant to help Harris County residents whose vision problems ... Even with corrective lenses, many people with low vision ... variety of low vision devices, such as telescopes, magnifiers ... , Iyer is using the three-year, $164,645 SightFirst grant ...
(Date:7/24/2014)... week for an all-day public forum on a $1.7 ... to dredge toxic sediment from an eight-mile stretch of ... the plan, which proposes removing 4.3 million cubic yards ... one of the largest cleanups in the agency,s history. ... , "We need to ensure the future well-being of ...
(Date:7/24/2014)... To reduce fire hazard in the United States, wildland ... woody shrubs and suppressed trees (ladder fuels). These ... periods of low fire danger in order to dispose ... hazardous air pollutants, managers often cover all or part ... referred to as agricultural plastic, in order to keep ...
Breaking Biology News(10 mins):UTHealth Dr. Bhavani Iyer awarded low vision grant 2Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2Study gives new perspective on agricultural plastic, debris burning, and air quality 2
... nanotechnology fanciers suggest that, like proverbial birds of ... or clump together. This tendency, they ... manufacturing increases and the number of nanotechnology-enabled products ... Maynard, chief science advisor to the Project on ...
... completing the first large-scale report sequencing breast and colon ... studied the vast majority of protein-coding genes which now ... mutated in relatively few cancers. Their report, published ... indicates that while little is known about these less-commonly ...
... a reality today, but how can we find out about ... a full record of the Earths climate for several hundred ... that can be taken to the lab for analysis. Incredibly, ... Antarctic regions, and a European Science Foundation programme has a ...
Cached Biology News:Nanoparticle exposures happen, says expert 2Genome update defines landscape of breast and colon cancers 2Genome update defines landscape of breast and colon cancers 3European lead in reading past climates from ice cores 2European lead in reading past climates from ice cores 3
... ESGRO Complete Derivation Kit is intended ... cells from delayed blastocysts in serum-free ... Clonal Grade ... Blastocyst Incubation Medium Trypsin Solution ...
AedestaTM Animal Organ/Tissue Perfusion Soln....
RAT ANTI MOUSE JAM-2 Immunogen: Recombinant soluble JAM-2...
casein kinase 2, alpha 1 polypeptide, transcript variant 2, mRNA (cDNA clone MGC:15232 IMAGE:4121882), complete cds...
Biology Products: